Pular para o conteúdo
Coriorretinopatia serosa central
ORPHA:443079CID-10 · H35.7CID-11 · 9B75.2DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Herança Unknown
Também conhecida comoRetinopatia serosa centralCSCR

A coriorretinopatia serosa central é uma doença que causa o acúmulo de líquido sob a retina, a parte posterior interna do olho que envia informações visuais para o cérebro. O líquido vaza da coroide (a camada de vasos sanguíneos sob a retina). A causa dessa condição é desconhecida, mas o estresse pode ser um fator de risco. Os sinais e sintomas incluem um ponto cego escuro e embaçado no centro da visão, distorção de linhas retas e ver objetos como menores ou mais distantes. Muitos casos de coriorretinopatia serosa central melhoram sem tratamento após 1 a 2 meses. O tratamento com laser pode ser uma opção para outros indivíduos.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

Mantido pelo Disease Twin100% com fonte · atualizado 23/09/2026Revisão médica pendente
Informacoes curadas por IA — podem conter imprecisoes

Visão geral

A coriorretinopatia serosa central é uma condição na qual ocorre o acúmulo de líquido sob a retina, que é a camada localizada na região posterior do olho responsável por enviar as informações visuais ao cérebro. Esse líquido é proveniente da coroide, a camada vascular subjacente à retina. Embora a causa exata seja desconhecida, o estresse é apontado como um possível fator de risco.[1]

Sinais e sintomas

Os sinais e sintomas descritos incluem a percepção de um ponto cego escuro e embaçado no centro do campo visual, distorção na visualização de linhas retas e a percepção de objetos como sendo menores ou situados a uma distância maior do que a real.[1]

Tratamento e manejo

Em muitos indivíduos, o quadro de coriorretinopatia serosa central apresenta melhora sem a necessidade de intervenção terapêutica após um período de 1 a 2 meses. Para determinados casos, a aplicação de tratamento com laser pode constituir uma alternativa de abordagem.[1]

Tratamentos citados na literatura

Dados obtidos por mineração de literatura científica apontam substâncias citadas em estudos associados à condição, não representando recomendações de tratamento: Verteporfin (146 publicações), Eplerenone (99 publicações), Bevacizumab (81 publicações), Fluorescein (64 publicações), Indocyanine Green (36 publicações), Spironolactone (35 publicações), Argon (34 publicações), Steroids (29 publicações), Ranibizumab (18 publicações) e Rifampin (14 publicações).[2]

Fontes numeradas em Referências.

Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.

💬
EM LINGUAGEM SIMPLES

A coriorretinopatia serosa central, também chamada de retinopatia serosa central, é uma condição em que ocorre vazamento de líquido sob a retina. A pessoa afetada percebe uma mancha embaçada no centro da visão, além de distorções em linhas retas e alterações na percepção visual de tamanho dos objetos. O estresse emocional ou físico é apontado como um dos fatores de risco associados ao quadro. Em muitos indivíduos, o problema se resolve de maneira espontânea em um a dois meses, embora aplicações de laser possam ser empregadas em outros casos. A doença não possui protocolo específico ou fornecimento de remédios dedicados no SUS, demandando avaliação na rede de referência médica.

Informacoes curadas por IA — podem conter imprecisoes
[1] Orphanet [2] GARD (NIH) [17] Ministério da Saúde — lista oficial de…
📋
Informacoes curadas por IA — podem conter imprecisoes

A coriorretinopatia serosa central é uma doença que causa o acúmulo de líquido sob a retina, a parte posterior interna do olho que envia informações visuais para o cérebro. O líquido vaza da coroide (a camada de vasos sanguíneos sob a retina). A causa dessa condição é desconhecida, mas o estresse pode ser um fator de risco. Os sinais e sintomas incluem um ponto cego escuro e embaçado no centro da visão, distorção de linhas retas e ver objetos como menores ou mais distantes. Muitos casos de coriorretinopatia serosa central melhoram sem tratamento após 1 a 2 meses. O tratamento com laser pode ser uma opção para outros indivíduos.

Pesquisas ativas
9 ensaios
81 total registrados no ClinicalTrials.gov
Publicações científicas
3.355 artigos
Último publicado: 2026 Mar
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: H35.7
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico3.355PubMed
Últimos 10 anos200publicações
Pico2025115 papers
Linha do tempo
2026Hoje · 2026🧪 2000Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado5
3Fase 36
2Fase 220
1Fase 13
·Pré-clínico47
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 81 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Coriorretinopatia serosa central

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 13 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

81 ensaios clínicos encontrados, 9 ativos.

Distribuição por fase
NCT07681167 · Faricimab for Chronic Central Serous Chorioretinopathy: A Ra…Em breve
PHASE2
NCT07767058 · Mindfulness for Central Serous ChorioretinopathyEm breve
NA🇬🇧 Reino Unido
NCT07298174 · Wide Field OCTA in Ocular DiseasesEm breve
NCT07347119 · Prospective Geometric Analysis of Ultra-Widefield OCTA Chara…Em breve
🇨🇳 China
NCT06809751 · Evaluating Efficacy and Safety of Oral Melatonin in Acute Ce…Em breve
PHASE2, PHASE3
NCT01327170 · Micropulse Diode Laser Treatment for Chronic Central Serous …Concluído
NA🇧🇷 Brasil
NCT05847049 · Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal …Concluído
🇪🇬 Egito
NCT04723160 · Computer Aided Diagnosis of Multiple Eye Fundus Diseases Fro…Concluído
🇨🇳 China
NCT04224831 · Treatment of Chronic Central Serous Chorioretinopathy Via El…Concluído
NATurkey (Türkiye)
NCT03497000 · Effects of OCTA-guided PDT in Acute CSCConcluído
NA🇨🇳 China
NCT03339856 · Selective Retina Therapy With Real-Time Feedback-Controlled …Concluído
NA
NCT02587767 · 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on …Concluído
NA🇨🇳 China
NCT03950089 · Optical Coherence Tomography Angiography (OCT-A) and Central…Concluído
NCT02784665 · Treatment Trial for Acute Central Serous ChorioretinopathyConcluído
NA🇨🇳 China
NCT03758963 · Selective Retina Therapy With 'R:GEN' in Patients With Centr…Concluído
NASouth Korea
NCT02735213 · Micropulse 577nm Laser vs Traditional Laser Treatment in Cen…Concluído
PHASE2, PHASE3🇨🇳 China
NCT05104138 · Eplerenone Versus PDT: Comparative Study by OCTAConcluído
NCT02354170 · Short-Term Oral Mifepristone for Central Serous Chorioretino…Concluído
PHASE2🇺🇸 Estados Unidos
NCT04356716 · Sildenafil for Treatment of Choroidal IschemiaConcluído
PHASE2🇺🇸 Estados Unidos
NCT02462499 · Eplerenone Treatment for Chronic Central Serous Chorioretino…Concluído
PHASE4Hungary
NCT01797861 · Prospective Randomized Controlled Treatment Trial for Chroni…Concluído
PHASE4🇫🇷 França · 🇩🇪 Alemanha · 🇳🇱 Países Baixos +1
NCT01971190 · Efficacy and Safety of Intravitreal Aflibercept Injection fo…Concluído
PHASE2South Korea
NCT01990677 · Eplerenone for the Treatment of Central Serous Chorioretinop…Concluído
NA🇺🇸 Estados Unidos
NCT01822561 · Eplerenone for Central Serous ChorioretinopathyConcluído
PHASE2🇺🇸 Estados Unidos
NCT02036632 · Eye Patch Therapy for Central Serous Retinopathy (CSR)Concluído
PHASE1🇺🇸 Estados Unidos
NCT01880788 · Genetic Analysis of Chronic Central Serous Chorioretinopathy…Concluído
🇺🇸 Estados Unidos
NCT01710332 · The Safety & Efficacy of Intravitreal Aflibercept Injection …Concluído
PHASE2🇺🇸 Estados Unidos
NCT01692938 · Evaluation of the Precision of the Microperimetry Function o…Concluído
🇺🇸 Estados Unidos
NCT01468337 · Topical Interferon Gamma-1b for Central Serous Chorioretinop…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01378130 · Central Serous Chorioretinopathy: Etiology, Course and Progn…Concluído
🇦🇹 Áustria
NCT01574430 · Study of Photodynamic Therapy (PDT) in Patients With Central…Concluído
PHASE4🇨🇳 China
NCT01227993 · Extension Study for the Evaluation of Finasteride in the Tre…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01325181 · Ranibizumab Versus Low-fluence Photodynamic Therapy in the T…Concluído
PHASE1, PHASE2South Korea
NCT00837252 · Pilot Study for the Evaluation of Finasteride in the Treatme…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01019668 · Central Serous Chorioretinopathy Treated by Modified Photody…Concluído
NA🇹🇼 Taiwan
NCT01434095 · Microperimetric Evaluation After Half-dose Photodynamic Ther…Concluído
NA🇯🇵 Japão
NCT00817245 · Effect of Helicobacter Pylori Treatment on Idiopathic Centra…Concluído
PHASE1, PHASE2Iran
NCT00803517 · Comparison of Multifocal Electroretinogram Assessment in Chr…Concluído
South Korea
NCT00802906 · Bevacizumab Versus Micropulse in Central Serous Chorioretino…Concluído
NA🇩🇪 Alemanha
NCT00489840 · Treatment of Chronic Central Serous Chorioretinopathy With O…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00987077 · Selective Retina Therapy (SRT) in Patients With Idiopathic C…Concluído
PHASE2🇩🇪 Alemanha
NCT00403325 · Intravitreal Ranibizumab Treatment of Central Serous Chorior…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00211393 · A Pilot Study of the Treatment of Central Serous Chorioretin…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00963131 · High-dose Antioxidants for Central Serous ChorioretinopathyConcluído
PHASE2Thailand
NCT00211445 · Photodynamic Therapy Using Verteporfin for Treatment of Chro…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00005784 · Evaluation and Treatment of Patients With Retinal DiseaseConcluído
🇺🇸 Estados Unidos
NCT06468540 · Combination of Micropulse Laser With or Without Photodynamic…UNKNOWN
NCT05633576 · Steroid Eye Drops in Chronic Central Serous Chorioretinopath…UNKNOWN
PHASE3🇳🇱 Países Baixos
NCT05687422 · Two Patterns of Micropulse Laser in the Treatment of Chronic…UNKNOWN
NA
NCT05570591 · Subthreshold Nanosecond Laser for Non-resolving Central Sero…UNKNOWN
NA🇦🇺 Austrália
NCT05589974 · Choroidal Blood Flow in Acute and Chronic Central Serous Cho…UNKNOWN
🇳🇴 Noruega
NCT05337332 · Results of Suprachoroidal Steroids Injections in Two Chorior…UNKNOWN
PHASE2, PHASE3🇪🇬 Egito
NCT05278169 · Central Serous Chorioretinopathy Registry and Pachychoroid O…UNKNOWN
Hong Kong
NCT04936490 · Crocin Supplementation in CSCRUNKNOWN
PHASE1Iran
NCT04665102 · Pilot Study on Deep Learning in the EyeUNKNOWN
NCT04410861 · Panmacular Versus Minimal Micropulse Laser Therapy in Centra…UNKNOWN
NAUnited Arab Emirates
NCT05390619 · Different Doses of vPDT in the Treatment of cCSCUNKNOWN
NA🇨🇳 China
NCT02681783 · PRedictive Factors and Changes From Treatment in iPCV Versus…UNKNOWN
PHASE4🇨🇦 Canadá
NCT03542006 · Brinzolamide for the Treatment of Chronic Central Serous Cho…UNKNOWN
PHASE2🇦🇷 Argentina · 🇮🇱 Israel
NCT03079141 · Photodynamic Therapy Versus Eplerenone: Treatment Trial for …UNKNOWN
PHASE4🇳🇱 Países Baixos
NCT03692169 · The Changes of Retinal Capillaries After Half-dose PDT Measu…UNKNOWN
🇨🇳 China
NCT02815176 · Angiographic Characteristics of CSC, PCV Patients and Thromb…UNKNOWN
South Korea
NCT02799992 · Pseudo-PDT in Central Serous ChorioretinopathyUNKNOWN
NA
NCT02215330 · A Study of the Beneficial Effects of Eplerenone on Central S…UNKNOWN
PHASE2, PHASE3🇦🇹 Áustria
NCT02153125 · Eplerenone For the Treatment of Chronic Central Serous Chori…UNKNOWN
PHASE2🇮🇱 Israel
NCT01633983 · Methotrexate for Central Serous Chorioretinopathy Treatment …UNKNOWN
PHASE2🇮🇱 Israel
NCT01630863 · The Safe Effective Light Dose of Photodynamic Therapy for Ch…UNKNOWN
NASouth Korea
NCT00864773 · The Effect of Therapy With Bevacizumab in Chronic Central Se…UNKNOWN
NA
NCT00403884 · Selective RPE Laser Treatment (SRT) for Various Macular Dise…UNKNOWN
NA🇩🇪 Alemanha
NCT05686421 · Comfortable and Stabilizing Chin & Forehead Rest Attachment …Encerrado
NA🇺🇸 Estados Unidos
NCT02889185 · Multimodal Imaging in Central Serous ChorioretinopathyEncerrado
NA🇫🇷 França
NCT01982383 · Study on the Use of Micropulse Laser to Treat Central Serous…Encerrado
NA🇺🇸 Estados Unidos
NCT01585441 · Finasteride for Chronic Central Serous ChorioretinopathyEncerrado
PHASE2🇺🇸 Estados Unidos
NCT02088151 · Selective Retinal Pigment Epithelium Laser Therapy for Macul…Encerrado
NA🇨🇭 Suíça
NCT05679180 · Navigated Microsecond Laser for Chronic Central Serous Chori…Cancelado
NA
NCT01256580 · Intravitreal Bevacizumab vs.Combination Therapy for CNV Due …Cancelado
NA
NCT00418431 · Intravitreal Bevacizumab for the Treatment of Central Serous…Cancelado
PHASE2, PHASE3🇲🇽 México
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
2.291 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.291

#1

Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.

International journal of molecular sciences2026 Jan 26

While standard anti- vascular endothelial growth factor (VEGF) therapy, with or without photodynamic therapy (PDT), is effective for patients with polypoidal choroidal vasculopathy (PCV), not all achieve optimal visual outcomes. This study aimed to compare fortified (double the dose and the volume of the standard one) anti-VEGF combined with PDT versus fortified anti-VEGF monotherapy and to investigate biomolecular profiles and disease relationships among PCV, neovascular age-related macular degeneration (nvAMD), and central serous chorioretinopathy (CSCR). The goal was to identify novel pathways to inform future therapeutic strategies, including hypoxia-inducible factors (HIF)-1α inhibitors. This retrospective cohort study included 23 eyes with indocyanine green-confirmed type C PCV. One eye treated with transpupillary thermotherapy was not included in the following two groups. Patients received either combined therapy (PDT + fortified-dose anti-VEGF; n = 12) or fortified-dose anti-VEGF monotherapy (n = 10). Primary outcomes were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Secondary outcomes included injection burden and recurrence. Exploratory analyses examined aqueous biomarkers, including VEGF, placental growth factor (PlGF), β-catenin, HIF-1α, and Wnt1 across PCV, CSCR, and nvAMD to identify novel therapeutic targets. Significant (p = 0.003/p = 0.005) median CRT reduction was similar (p = 0.468) between groups (combined/monotherapy: 137.5 µm/106.5 µm). BCVA (median [Q1, Q3]) change in logarithm of the minimum angle of resolution (LogMAR) was not statistically significant (p = 0.279), with 0.25 [0.00, 0.98] in the combined group versus 0.00 [-0.03, 0.28] in the monotherapy group. Treatment burden of anti-VEGFs per person per year was lower with combined therapy (1.16 ± 0.47# PDT + 2.81 ± 0.92# anti-VEGF injections) compared with monotherapy (4.61 ± 1.49# injections). Six eyes demonstrated recurrence at a mean of 15.5 months. Incomplete regression of polyps and branching vascular networks was observed in all eyes. Exploratory biomarker analysis revealed significantly (p < 0.05) higher VEGF and PlGF levels in nvAMD compared with PCV. nvAMD also demonstrated significantly (p < 0.05) higher β-catenin and lower HIF-1α levels relative to PCV and CSCR, while no significant biomarker differences were observed between PCV and CSCR. Combined therapy or monotherapy with fortified anti-VEGFs reduced treatment burden and achieved significant anatomical improvement but did not yield superior functional outcomes, highlighting the therapeutic difficulty of type C PCV. Biomarker profiling revealed shared hypoxia-related mechanisms between PCV and CSCR, with elevated HIF-1α compared to nvAMD indicating a "preliminary" possible role for HIF-1α inhibitors. Differential expression of these biomarkers highlights additional molecular pathways that may inform future targeted interventions.

#2

Correction: Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy.

PloS one2026

[This corrects the article DOI: 10.1371/journal.pone.0282057.].

#3

The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy.

Ophthalmology science2026 Feb

To evaluate the effects of haplotype-tagging single nucleotide polymorphisms (SNPs) in the complement factor H-complement factor H related 5 (CFH-CFHR5) locus on neovascular age-related macular degeneration (nAMD), polypoidal choroidal vasculopathy (PCV), and chronic central serous chorioretinopathy (cCSCR) in Chinese patients. Case-control genetic association study. A total of 846 patients (341 nAMD, 288 PCV, and 217 cCSCR including 43 with secondary macular neovascularization [MNV]) and 632 healthy Chinese controls. A total of 17 candidate SNPs were initially selected from the CFH-CFHR5 region; after excluding 5 SNPs that deviated from Hardy-Weinberg equilibrium, 12 SNPs were retained for the final analysis. Association analyses included logistic regression adjusted for age and sex and haplotype-based analysis using Haploview. Study-wide significance threshold was set at P < 0.0042 for allelic tests (Bonferroni-corrected for 12 SNPs) and at P < 0.05 for haplotype tests (adjusted using 10 000 permutations). Associations between individual SNPs and haplotypes in the CFH-CFHR5 locus with nAMD, PCV, and cCSCR (with or without MNV), respectively. The tagging SNP, rs12144939, for the CFHR3/1 deletion was significantly associated with nAMD (odds ratio [OR] = 0.37, P = 0.0031). Notably, we identified 3 candidate variants showing novel associations with PCV, including rs12144939 (OR = 0.29, P = 6.29 × 10-4), rs423641 in CFHR1 (OR = 0.74, P = 0.0038), and rs10922152 in CFHR5 (OR = 1.55, P = 0.0031). No SNP in this locus was associated with cCSCR without MNV, whereas CFH rs529825 was nominally associated with cCSCR with MNV (OR = 0.47, P = 0.0047). Similar patterns of haplotype associations were observed across the 3 maculopathies. Notably, the haplotype A-T-C-G spanning CFHR4, CFHR2, and CFHR5 (OR = 1.81, permutation P = 0.0099) and haplotype G-A-G within CFHR5 (OR = 1.56, permutation P = 0.025) were specifically associated with PCV. This study validates the association of the CFHR3/1 deletion (tagged by rs12144939) with nAMD. Furthermore, we reveal a novel genetic architecture for PCV within the CFH-CFHR5 locus, characterized by associations at rs12144939, rs423641 (CFHR1), and rs10922152 (CFHR5), as well as risk haplotypes unique to PCV. These findings underscore the critical role of CFH-related genes in PCV and provide new insights into its genetic mechanisms. The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.

#4

Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.

Translational vision science &amp; technology2026 Jan 05

We evaluated the clinical outcomes of selective retina therapy (SRT) with fundus image-based titration approach for central serous chorioretinopathy (CSC). Sixty eyes (60 participants) with chronic CSC prospectively underwent SRT. Treatment (527-nm wavelength, 1.7-µs pulse duration) targeted leakage sites identified via fundus fluorescein angiography. Pulse energy and micropulse number were adjusted based on test-spot fundus images. Changes in best-corrected visual acuity (BCVA), central foveal thickness, subfoveal choroidal thickness, and subretinal fluid (SRF) height were evaluated at baseline and at 1, 2, and 3 months post treatment. Retinal sensitivity was measured by microperimetry at baseline and 3 months. Outcomes were compared between eyes with completely resolved or residual SRF at 3 months. At 3 months, complete SRF resolution was observed in 80.8% of eyes (42/52). The mean SRF height decreased from 135.6 ± 81.9 µm to 28.0 ± 72.0 µm, and the mean central foveal thickness from 318.9 ± 88.0 µm to 231.9 ± 69.8 µm (both P < 0.001). In parallel, functional parameters also improved, with mean best-corrected visual acuity increasing from 0.17 ± 0.15 logarithm of the minimum angle of resolution to 0.06 ± 0.12 logarithm of the minimum angle of resolution and mean deviation of retinal sensitivity from -0.89 ± 1.65 dB to 0.02 ± 1.29 dB (both P < 0.001). Female sex was significantly associated with persistent SRF in both univariate and multivariable analyses (odds ratio, 30.794; 95% confidence interval, 2.996-774.668; P = 0.011). SRT with fundus image-based titration yielded favorable functional and anatomical outcomes in CSC. Female sex was associated with persistent SRF, although this finding should be interpreted cautiously. Fundus image-based titration translates selective retinal pigment epithelium targeting in selective retina therapy into a reproducible clinical approach for central serous chorioretinopathy. This strategy facilitates individualized treatment while remaining compatible with routine clinical practice.

#5

Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.

Translational vision science &amp; technology2026 Jan 05

Accurate classification of retinal diseases such as dry age-related macular degeneration, wet AMD, epiretinal membrane, full-thickness macular hole (MH), lamellar MH, and central serous chorioretinopathy (CSC) is essential for effective treatment and clinical decision-making. Traditional deep learning models, however, often struggle with imbalanced datasets and lack interpretability, limiting their translational applicability in ophthalmology. We propose a neurosymbolic framework that integrates a convolutional neural network (CNN) with a symbolic reasoning layer based on expert-defined clinical rules. A total of 10,846 optical coherence tomography images were retrospectively collected and categorized into seven diagnostic classes: dry AMD, wet AMD, epiretinal membrane, full-thickness MH, lamellar MH, central serous chorioretinopathy, and healthy retinas. Our neurosymbolic model achieved macro-precision 0.83, recall 0.82, and F1 0.81, on internal dataset, having slightly better performance than the CNN (0.64/0.83/0.68). On the external dataset, it retained superior performance, macro-precision 0.85, recall 0.79, F1 0.78, versus the CNN (0.73/0.64/0.59). Our hybrid neurosymbolic framework introduces a unified paradigm that couples symbolic reasoning with a conventional CNN, improving diagnostic performance while delivering transparent, clinically interpretable decisions. It is particularly effective for rare and complex conditions that often challenge end-to-end deep learning models. By integrating symbolic clinical logic with visual pattern recognition, the neurosymbolic model fosters trust in artificial intelligence-assisted diagnostics and supports precise, explainable decision-making in retinal care.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.623 artigos no totalmostrando 196

2026

CLINICAL AND IMAGING PREDICTORS OF BILATERAL INVOLVEMENT IN CENTRAL SEROUS CHORIORETINOPATHY.

Retina (Philadelphia, Pa.)
2026

Anterior uveal morphometrics in complex central serous chorioretinopathy: insights from ultrasound biomicroscopy and anterior segment optical coherence tomography.

Clinical &amp; experimental optometry
2026

Prognostic value of foveal choroidal vascular hyperpermeability on indocyanine green angiography in central serous chorioretinopathy.

Eye (London, England)
2026

Assessment of artifact-removed choriocapillaris flow voids in eyes with pachychoroid spectrum disorders.

Japanese journal of ophthalmology
2026

Ultra-widefield indocyanine green angiography findings of vortex veins in central serous chorioretinopathy.

Japanese journal of ophthalmology
2026

Long-term follow-up of PLACE and SPECTRA trials: outcomes after successful and unsuccessful half-dose photodynamic therapy for chronic central serous chorioretinopathy.

American journal of ophthalmology
2026

Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: An updated systematic review and meta-analysis.

Survey of ophthalmology
2026

Association Between Pseudoexfoliation Glaucoma and Central Serous Chorioretinopathy.

American journal of ophthalmology
2026

Inner Collagenous Layer Detachment: A Novel Optical Coherence Tomography Sign in Avascular Serous Pigment Epithelial Detachment Secondary to Central Serous Chorioretinopathy.

Ophthalmic surgery, lasers &amp; imaging retina
2026

Hormonal factors in the pathophysiology of central serous chorioretinopathy - a systematic review and meta-analysis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of static and dynamic pupillometry parameters in patients with central serous chorioretinopathy.

European journal of ophthalmology
2026

Central Serous Chorioretinopathy is Associated with Increased Cardiovascular Risk: An Artificial Intelligence-Based Retinal Analysis.

Ophthalmic epidemiology
2026

Childhood central serous chorioretinopathy: An uncommon cause of neurosensory macular detachment.

Archivos de la Sociedad Espanola de Oftalmologia
2026

Central Serous Chorioretinopathy in Parallel With Onset and Relapses of Minimal Change Nephrotic Syndrome: A 28-Year Case Follow-Up.

Cureus
2026

A bibliometric and visualized analysis of choriocapillaris from 2013 to 2023.

International journal of ophthalmology
2026

An intelligent segmentation method for leakage points in central serous chorioretinopathy based on fluorescein angiography images.

International journal of ophthalmology
2026

Demography, Clinical Characteristics and Long-Term Outcomes of Central Serous Chorioretinopathy in Women. MICRoN Report Number Fourteen.

American journal of ophthalmology
2026

Clinical Characteristics and Outcomes in Central Serous Chorioretinopathy with Subretinal Hyper-Reflective Material: MICRoN report 6.

American journal of ophthalmology
2026

Update on subthreshold micropulse laser treatment for retinal diseases: A narrative review.

Survey of ophthalmology
2026

Chronic Central Serous Chorioretinopathy with and without Myopia: Clinical Features and Response to Half-Dose Photodynamic Therapy.

Photodiagnosis and photodynamic therapy
2026

Eplerenone for Central Serous Chorioretinopathy: Is There Still Room for This Treatment?

Biomedicines
2025

Corticosteroid-induced central serous chorioretinopathy in a pemphigus vulgaris patient.

Dermatology online journal
2026

Outer Retinal Erosion and Outer Retinal Pinching at the Origin of Subretinal Fluid in Central Serous Chorioretinopathy.

American journal of ophthalmology
2026

The Amsler Grid in Everyday Practice: A Review of Its Role and Limitations in Primary Care.

Clinical ophthalmology (Auckland, N.Z.)
2026

Choroidal imaging biomarkers as predictors of recurrent central serous chorioretinopathy: A multicenter retrospective study - MICRoN report number five.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Secondary Multiple Evanescent White Dot Syndrome Associated with Active Central Serous Chorioretinopathy.

Retinal cases &amp; brief reports
2026

Choriocapillaris flow deficits and choroidal vascular index in the fellow eye of patients with central serous chorioretinopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Combined Therapy Versus Fortified Anti-VEGF Monotherapy in Type C Polypoidal Choroidal Vasculopathy: Long-Term Outcomes and Exploratory Biomarker Insights.

International journal of molecular sciences
2026

The Role of Nailfold Videocapillaroscopy (NVC) in Evaluating Ocular Diseases: Insights into Retinal, Choroidal, and Optic Nerve Pathologies.

Journal of clinical medicine
2026

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.

Acta ophthalmologica
2026

Increased peripapillary choroidal blood flow velocity in peripapillary pachychoroid syndrome: Three case reports with referential observations in central serous chorioretinopathy.

American journal of ophthalmology case reports
2026

Central Serous Chorioretinopathy: Etiology, Diagnosis, and Treatment.

Deutsches Arzteblatt international
2026

Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.

Acta ophthalmologica
2026

Association between central serous chorioretinopathy and personality types: A systematic review and meta-analysis.

Acta ophthalmologica
2026

Efficacy of Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Retrospective Analysis at Hanusch Hospital, Vienna.

Klinische Monatsblatter fur Augenheilkunde
2026

Prevalence and associations of central serous chorioretinopathy in a population aged 50+ years. The Beijing Eye Study.

Eye (London, England)
2026

Large-caliber choroidal arteriovenous shunt in macular neovascularization: A brief report of a novel morphological finding.

Photodiagnosis and photodynamic therapy
2026

Hyperreflective choroidal foci may predict pachychoroid macular atrophy development in central serous chorioretinopathy.

Eye (London, England)
2026

Dichotomous pathogenesis drives therapeutic choice: A case report and review of literature differentiating glucocorticoid-induced from disease activity-associated central serous chorioretinopathy in lupus nephritis.

Lupus
2026

Proteomic Signature in Men with Central Serous Chorioretinopathy.

Journal of proteome research
2026

Venous Overload Choroidopathy With Coexisting Chronic Central Serous Chorioretinopathy and Uveal Effusion Syndrome.

Journal of vitreoretinal diseases
2026

The CFH-CFHR5 Locus in Wet Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, and Central Serous Chorioretinopathy.

Ophthalmology science
2026

Peripapillary intervortex venous anastomoses in central serous chorioretinopathy.

International ophthalmology
2025

Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review.

Frontiers in medicine
2026

Dim Flicker: An Endogenous Visual Percept and Its Disease Associations.

Journal of clinical medicine
2026

Vitreoretinal disease detection using artificial intelligence: a systematic review and meta-analysis.

International ophthalmology
2026

Bilateral Central Serous Chorioretinopathy in a Patient With XYY Syndrome.

Ophthalmic surgery, lasers &amp; imaging retina
2026

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy.

International journal of ophthalmology
2026

Elevated Anxiety Levels in Central Serous Chorioretinopathy: Evidence from a Prospective Case-Control Study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2026

Selective Retina Therapy With Fundus Image-Based Titration in Central Serous Chorioretinopathy: Prospective Outcomes and Predictive Factors.

Translational vision science &amp; technology
2026

Neurosymbolic AI Framework for Explainable Retinal Disease Classification From OCT Images.

Translational vision science &amp; technology
2026

Exploring retinal and choroidal characteristics on multimodal imaging in resolved central serous chorioretinopathy.

Eye (London, England)
2025

Punctate Hyperfluorescent Spots on Indocyanine Green Angiography in Eyes with Central Serous Chorioretinopathy and Patient Demographics.

Journal of clinical medicine
2025

A Novel Panmacular Strategy for Subthreshold Micropulse Laser in CSC: Two-Year Functional and Morphological Outcomes.

Journal of clinical medicine
2026

Long-term outcomes of titration-guided focal selective retina therapy for chronic central serous chorioretinopathy: retrospective real-world data analysis.

BMC ophthalmology
2026

Optical density ratio as a prognostic biomarker for chronicity in Central Serous Chorioretinopathy.

Retina (Philadelphia, Pa.)
2025

The "scolex" sign" - A distinct hyperreflective foci on the wall of serous pigment epithelial detachments in central serous chorioretinopathy - MICRON Report Number Seven.

Retina (Philadelphia, Pa.)
2025

Evaluation of Changes in Optical Coherence Tomography (OCT) Biomarkers After Oral Eplerenone Therapy in Chronic Central Serous Chorioretinopathy and Their Correlation to Functional Visual Outcome.

Cureus
2026

Pilot Study of Choroidal Synphlebia.

Retina (Philadelphia, Pa.)
2025

Imaging characteristics of macular neovascularization in chronic central serous chorioretinopathy patients.

Retina (Philadelphia, Pa.)
2025

A deeper assessment of various choroidal and demographic biomarkers among symptomatic pachychoroid spectrum entities within a tertiary referral center.

Retina (Philadelphia, Pa.)
2025

A deep learning-based pachychoroid index based on choroidal image patterns of central serous chorioretinopathy using enhanced-depth-imaging optical coherence tomography.

Japanese journal of ophthalmology
2025

Bilateral Central Serous Chorioretinopathy Associated With Tuberculosis in a Female Patient.

Cureus
2026

REDUCTION OF SCLERAL THICKNESS WITH TOPICAL FLUOROMETHOLONE IN MANAGEMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY COMPLICATED BY POSTERIOR CYSTOID DEGENERATION.

Retinal cases &amp; brief reports
2025

Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma.

GMS ophthalmology cases
2025

EXOGENOUS TESTOSTERONE USE AND ACUTE CENTRAL SEROUS CHORIORETINOPATHY IN A TRANSGENDER PATIENT.

Retinal cases &amp; brief reports
2025

Oral Eplerenone for Exudative Retinal Detachment Secondary to Central Serous Chorioretinopathy: A Case Report.

Cureus
2026

A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II.

American journal of ophthalmology
2026

The spectrum of pachychoroid neovasculopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Pachychoroid pigment epitheliopathy and macular venous outflow abnormalities: the effects of venous stasis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis.

BMC ophthalmology
2025

Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents.

International journal of molecular sciences
2025

Multimodal imaging predictors of recurrence after photodynamic therapy in chronic central serous chorioretinopathy.

International ophthalmology
2025

Full-Spectrum Pachychoroid Manifestation in One Eye: A Case Report.

Case reports in ophthalmology
2025

A coarse-to-fine registration method for multimodal retinal images.

Scientific reports
2025

Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta-analysis.

Acta ophthalmologica
2025

Choroidal neovascularization as a trigger for central serous chorioretinopathy.

International journal of retina and vitreous
2025

Systemic C-reactive protein levels and central serous chorioretinopathy: A systematic review with meta-analysis.

Acta ophthalmologica
2025

Short-Term Topical Minoxidil Use Associated with Acute Central Serous Chorioretinopathy: A Case Report.

Case reports in ophthalmology
2025

When Erectile Dysfunction Therapy Clouds the Vision: ST-BRVO after Sildenafil in a Healthy Male.

Case reports in ophthalmology
2026

Subretinal Fluid Duration and Clinical Outcomes in Central Serous Chorioretinopathy: An Analysis of Time-to-Photodynamic Therapy.

American journal of ophthalmology
2025

Exogenous Hormone Use as a Predictor of Central Serous Chorioretinopathy Recurrence: A Comparative Analysis of Observation Versus Low-Fluence Photodynamic Therapy.

Journal of vitreoretinal diseases
2025

Selective retina therapy for central serous chorioretinopathy with focal choroidal excavation: a retrospective case series of six eyes.

International journal of retina and vitreous
2026

Clinical Features and Outcomes of Bullous Central Serous Chorioretinopathy: A Multicentric Cohort Study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
2025

Hyperreflective Choroidal Foci: A Comprehensive Review.

Journal of ophthalmic &amp; vision research
2026

Three-dimensional choroidal vessels assessment in central serous chorioretinopathy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of Long-Term Ocular Findings in Liver Transplant Patients: Comparison of Pediatric and Adult Age Groups.

Transplantation proceedings
2025

Three-Dimensional Choroidal Contour Mapping in Central Serous Chorioretinopathy and Fellow Eyes.

Translational vision science &amp; technology
2025

Visual Disturbance During Pregnancy: A Case Report of Central Serous Chorioretinopathy.

Cureus
2025

The urinary 6-sulfatoxymelatonin level in patients with central serous chorioretinopathy and its correlation with choroidal vasculature.

International ophthalmology
2025

A comparative study of choroidal thickness and pigment epithelial detachment in acute and chronic central serous chorioretinopathy in Nepalese patients.

PloS one
2026

Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis.

Neurology and therapy
2025

Half-time photodynamic therapy for serous pigment epithelium detachment: anatomical and functional outcomes.

Photodiagnosis and photodynamic therapy
2026

Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.

Ophthalmology and therapy
2025

Advances in minimally traumatic retinal laser therapy.

Expert review of medical devices
2025

Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome.

International ophthalmology
2026

Association of Migraine With Increased Risk of Central Serous Chorioretinopathy: A Retrospective Cohort Study.

American journal of ophthalmology
2026

Volumetric choroidal biomarkers in central serous chorioretinopathy using swept-source optical coherence tomography: a deep learning approach.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Retinal fingerprint pattern in central serous chorioretinopathy.

Retina (Philadelphia, Pa.)
2026

DIAGNOSTIC PERFORMANCE OF MACHINE LEARNING TECHNOLOGY USING OPTICAL COHERENCE TOMOGRAPHIC IMAGE IN RETINAL DISEASES PRESENTED WITH SUBRETINAL FLUID.

Retina (Philadelphia, Pa.)
2026

Corneal Nerve Abnormalities in Chronic Central Serous Chorioretinopathy.

Ophthalmology science
2025

Embossing enhances visualization of retinal pigment epithelium alterations in fundus autofluorescence in central serous chorioretinopathy.

European journal of ophthalmology
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Response to Letter].

Clinical ophthalmology (Auckland, N.Z.)
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Letter].

Clinical ophthalmology (Auckland, N.Z.)
2025

Changes in choriocapillaris blood flow following half-fluence, full-dose photodynamic therapy (PDT) and half-fluence, half-dose PDT in patients with central serous chorioretinopathy: A quantitative analysis of early post-treatment alterations.

Photodiagnosis and photodynamic therapy
2025

International consensuses and guidelines on central serous chorioretinopathy (CSC) by the Asia Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI).

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
2025

Non-Neoplastic Disorders Mimicking Posterior Segment Inflammation.

Ocular immunology and inflammation
2025

Evaluation of Leak Sites in Central Serous Chorioretinopathy and the Effects of PDT on RPE by Polarization-Sensitive OCT.

Translational vision science &amp; technology
2026

Predictors of persistent central serous chorioretinopathy: a multicenter retrospective study - MICRoN report number four.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2026

Evaluation of choriocapillaris perfusion changes in chronic central serous chorioretinopathy following Half-Dose photodynamic therapy.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Bilateral Choroidal Metastases Mimicking Central Serous Chorioretinopathy: A Diagnostic Challenge.

Cureus
2025

Secondary Choroidal Osteoma in the Setting of Uveal Pathology: 4 Case Reports and Review.

Ocular oncology and pathology
2026

THE ROLE OF EN FACE IMAGING OF RETINAL PIGMENT EPITHELIUM ALTERATIONS IN RAPID CLASSIFICATION OF CENTRAL SEROUS CHORIORETINOPATHY USING WIDEFIELD SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY.

Retina (Philadelphia, Pa.)
2025

A comprehensive overview: deep learning approaches to central serous chorioretinopathy diagnosis.

BMC ophthalmology
2026

Exogenous Testosterone Use Increases the Risk of Central Serous Chorioretinopathy.

American journal of ophthalmology
2025

Comparative efficacy of two different subthreshold yellow laser treatments for chronic central serous chorioretinopathy.

Journal francais d'ophtalmologie
2025

Pachychoroid Neovasculopathy, Intravitreal Injection, and Implications for Aeromedical Decision Making.

Aerospace medicine and human performance
2025

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

Clinical ophthalmology (Auckland, N.Z.)
2024

Cyclodialysis Cleft following Intravitreal Injection; Case Report.

Journal of current ophthalmology
2025

Choroidal Vascular Fingerprints From Indocyanine Green Angiography Unveil Chorioretinal Disease State.

Investigative ophthalmology &amp; visual science
2026

Association between Choroidal Vascular Hyperpermeability and Vortex Vein Anastomoses in Central Serous Chorioretinopathy.

Ophthalmology science
2025

Pregnancy as a risk factor for central serous chorioretinopathy: A systematic review and meta-analysis.

Acta ophthalmologica
2025

Diagnostic and Management Challenges in Atypical Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: A Case Report.

Cureus
2025

Flat irregular pigment epithelium detachments in chronic central serous chorioretinopathy: a focus on choroidal changes.

Eye (London, England)
2025

Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study.

Journal of personalized medicine
2025

Micropulse laser therapy at 532, 577, and 810 nm for chronic central serous chorioretinopathy: a systematic review and Meta-analysis.

International journal of ophthalmology
2025

An autopsy case of bullous retinal detachment and hypopyon in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.

American journal of ophthalmology case reports
2025

National study on the management of central serous chorioretinopathy.

Archivos de la Sociedad Espanola de Oftalmologia
2026

Double layer sign in chorioretinal diseases: Clinical significance and implications from multimodal imaging.

Survey of ophthalmology
2025

Association of Central Serous Chorioretinopathy With Endogenous or Exogenous Corticosteroids: A Report of 2 Cases.

JCEM case reports
2025

Efficacy of Topical Non-Selective and COX-2 Selective NSAIDs in Accelerating Resolution of Acute Central Serous Chorioretinopathy: A Retrospective Analysis.

Clinical ophthalmology (Auckland, N.Z.)
2025

Efficacy of subliminal laser in chronic central serous chorioretinopathy: A 2.5-Year retrospective study.

Lasers in medical science
2025

Choroidal vascular hyperpermeability patterns in central serous chorioretinopathy correlate with microperimetry: CERTAIN study report 4.

Acta ophthalmologica
2026

Clinical and imaging characteristics of central serous chorioretinopathy with subfoveal leak.

European journal of ophthalmology
2025

Resolved Central Serous Chorioretinopathy Mimicking Hydroxychloroquine Toxicity: A Case Series and Literature Review.

Diagnostics (Basel, Switzerland)
2025

Central Serous Chorioretinopathy and Diagnostic Challenges in Emergency Settings.

Advanced emergency nursing journal
2025

Three-Dimensional Choroidal Vessels Assessment in Fellow Eyes of Patients With Central Serous Chorioretinopathy.

Translational vision science &amp; technology
2025

Evaluation of Reflectivities of RPE, ELM, EZ, and Their Relationship With Subretinal Fluid Properties in Central Serous Chorioretinopathy.

Investigative ophthalmology &amp; visual science
2025

Classifying Subretinal Lucency: A Matter of Terminology and Resolution.

Retina (Philadelphia, Pa.)
2025

Predictive factors for the development of macular neovascularization in chronic central serous chorioretinopathy.

Scientific reports
2025

Morphological and Functional Outcomes in the Long-Term Natural Course of Peripapillary Pachychoroid Syndrome.

Ophthalmology and therapy
2025

Visual Acuity May Inadequately Reflect the Vision-related Quality of Life in Patients with Chronic Chorioretinopathy Centralis Serosa.

Klinische Monatsblatter fur Augenheilkunde
2025

Central serous chorioretinopathy imaging biomarkers as potential indicators of response to subthreshold nanosecond laser.

Indian journal of ophthalmology
2026

Controversies and conundrums in pachychoroid spectrum disorders: A structured diagnostic approach.

Survey of ophthalmology
2025

A Lightweight CNN for Multiclass Retinal Disease Screening with Explainable AI.

Journal of imaging
2025

A Novel Finding of Retinal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy.

Cureus
2025

Taxane-associated retinopathy and radiation-induced optic neuropathy in a young female patient with metastatic breast cancer.

GMS ophthalmology cases
2025

Choriocapillaris perfusion assessed using optical coherence tomography angiography depends on eye color and projection artifact removal.

International ophthalmology
2025

Large Retinal Pigment Epithelium Tear in Central Serous Chorioretinopathy.

Ophthalmology. Retina
2025

Hyperreflective Foci in Blowout Pigmented Epithelium Detachment Secondary to Pachychoroid Mimicking Type 3 Macular Neovascularization.

Ophthalmic surgery, lasers &amp; imaging retina
2025

CPAP Use and Retinal Disease Risk in Obstructive Apnea: A Cohort Study.

Vision (Basel, Switzerland)
2025

Intraocular Pressure and Ocular Perfusion Pressure in Central Serous Chorioretinopathy.

American journal of ophthalmology
2025

[Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].

Die Ophthalmologie
2025

Approach to optic disc swelling with macular subretinal fluid and choroidal folds: a narrative review.

Photodiagnosis and photodynamic therapy
2025

Remarkable response to dupilumab in refractory allergic bronchopulmonary mycosis with a giant mucus plug due to Aspergillus udagawae.

Respiratory investigation
2025

Anatomical and Functional Outcomes of Anti-VEGF Therapy in Pachychoroid Neovasculopathy.

Clinical ophthalmology (Auckland, N.Z.)
2025

Clinical Features and Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration and Pachychoroid Neovasculopathy.

Journal of vitreoretinal diseases
2026

Central Serous Chorioretinopathy occurs in High Frequency in Myelin Oligodendrocyte Glycoprotein Antibody Disease, Seropositive and Seronegative Neuromyelitis Optica Spectrum Disorders compared to Multiple Sclerosis and Healthy Controls.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2025

Impact of the COVID-19 pandemic on the incidence and recurrence of central serous chorioretinopathy in Greece: a multicenter study.

International ophthalmology
2025

A case of macular damage following micropulse laser treatment for central serous chorioretinopathy.

The Journal of international medical research
2025

Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.

Ophthalmology and therapy
2025

Changes in choroidal vessel morphology associated with fluid leakage in central serous chorioretinopathy; a comparison of OCTA and ICGA.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Evaluation of Choroidal Vein Distribution Pattern and Choroidal Vessel Parameters in Patients With Central Serous Chorioretinopathy Using Widefield ICGA and Widefield OCTA.

American journal of ophthalmology
2026

Deep learning in central serous chorioretinopathy.

Survey of ophthalmology
2025

Two-year treatment outcome of photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.

Photodiagnosis and photodynamic therapy
2025

Association of central serous chorioretinopathy with single-nucleotide polymorphisms in Complement Factor H gene in a Chinese population.

International ophthalmology
2025

Central Serous Chorioretinopathy.

Advances in experimental medicine and biology
2025

Comprehensive analysis of pachyvessel morphology in central serous chorioretinopathy using multimodal imaging.

Scientific reports
2025

Characteristics of vortex vein in healthy eyes and fundus diseases imaged by ultra-widefield OCTA.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2025

Evaluation of the therapeutic effects of smoking cessation on chronic central serous chorioretinopathy.

Scientific reports
2025

Acute bilateral retinal and choroidal detachment - A case report.

Retinal cases &amp; brief reports
2025

Research Progress in Artificial Intelligence for Central Serous Chorioretinopathy: A Systematic Review.

Ophthalmology and therapy
2025

Dark Adaptometry Kinetics Differentiates Age-Related Macular Degeneration from Central Serous Chorioretinopathy.

Ophthalmology science
2025

Comparison of microvasculature between neovascular, non-neovascular chronic central serous chorioretinopathy cases and asymptomatic fellow eyes using swept-source optical coherence tomography angiography.

International ophthalmology
2025

Photodynamic therapy-induced inflammation and adverse effects: An updated review.

Biomedical journal
2025

Central serous chorioretinopathy mimicking as choroidal hemangioma - A diagnostic challenge.

Oman journal of ophthalmology
2025

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up.

Clinical ophthalmology (Auckland, N.Z.)
2025

Photodynamic therapy on chronic pathology during the post-COVID19 and worldwide shortage of verteporfin (Visudyne®) era.

Photodiagnosis and photodynamic therapy
2025

A Comparative Study on the Prevalence of Helicobacter pylori Infection in Patients with Central Serous Chorioretinopathy versus a Control Population.

Clinical ophthalmology (Auckland, N.Z.)
2025

Treatment of central serous chorioretinopathy: new options for an old disease.

Eye (London, England)
2026

Successful surgical repair of a ruptured medial rectus muscle accompanied with serous chorioretinopathy.

Strabismus
2025

Analysis of cytokine profiles in aqueous humor based on optical coherence tomography in pachychoroid spectrum diseases.

Scientific reports
2025

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.

International journal of ophthalmology
2025

Interventions for central serous chorioretinopathy: a network meta-analysis.

The Cochrane database of systematic reviews
2025

Reduction in choroidal thickness associated with the progression of pachychoroid spectrum diseases.

Japanese journal of ophthalmology
2025

Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis.

American journal of ophthalmology
2025

Three-Dimensional Choroidal Contour Mapping in Healthy and Diseased Eyes.

Translational vision science &amp; technology
2025

The results of subthreshold 577 nm yellow laser application using pascal laser system in patients with chronic central serous chorioretinopathy.

Lasers in medical science
2025

Case Report: Kyrieleis plaques in an unusual Behcet's disease uveitis.

Frontiers in medicine
2025

Delayed Onset of Central Serous Chorioretinopathy following Corticosteroid Treatment for Giant Cell Arteritis: A Case Report.

Case reports in ophthalmology
2025

Posterior scleritis misdiagnosed as central serous chorioretinopathy: Case report.

Photodiagnosis and photodynamic therapy
2025

Central serous chorioretinopathy and autonomic dysfunction.

Indian journal of ophthalmology
2025

Evaluation of anterior scleral thickness in eyes with central serous chorioretinopathy.

Indian journal of ophthalmology
2025

Real-world use of a hydrophilic curcumin-based oral formulation in the management of macular oedema: a collection of clinical experiences.

Drugs in context
2025

Fractal analysis for OCT-A images of central serous chorioretinopathy.

Photodiagnosis and photodynamic therapy
Ver todos os 2.623 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Coriorretinopatia serosa central.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Coriorretinopatia serosa central e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A causa exata dessa condição ainda é desconhecida pela medicina. O estresse é reconhecido como um importante fator de risco associado ao surgimento do problema.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

4 fontes citadas no texto · 10 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. MONDO
    purl.obolibrary.org
  2. GARD:200
    GARD (NIH)
  3. Q1431217
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (2026). Coriorretinopatia serosa central. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/coriorretinopatia-serosa-central

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Coriorretinopatia serosa central
Compêndio · Raras BR

Coriorretinopatia serosa central

ORPHA:443079 · MONDO:0018616
CID-10
H35.7 · Separação das camadas da retina
CID-11
Ensaios
9 ativos
MedGen
UMLS
C0730328
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Rara